Please wait a minute...
Reviews in Cardiovascular Medicine  2014, Vol. 15 Issue (S1): 21-29     DOI: 10.3908.ricm15S1S005
Review Previous articles | Next articles
Impact of Nucleoside Reverse Transcriptase Inhibitors on Coronary Heart Disease
Patrick W.G. Mallon
HIV Molecular Research Group, School of Medicine and Medical Science, University College Dublin, Ireland
Download:  PDF(243KB)  ( 19 )
Export:  BibTeX | EndNote (RIS)      
Abstract:
The nucleoside and nucleotide reverse transcriptase inhibitor (N[t]RTI) drug class remains an integral component of effective antiretroviral therapy (ART) for human immunodeficiency virus (HIV) infection. However, these drugs are associated with toxicities, through their off-target effects, that may significantly contribute to a number of long-term comorbidities, including coronary artery disease (CAD) and myocardial infarction (MI), recognized to occur with increased frequency in those with HIV undergoing treatment with ART. The contribution of N(t)RTI to CAD and MI may arise either indirectly through induction of metabolic toxicities such as dyslipidemia and insulin resistance, or directly through impact on pathologic pathways involved in development of MI, such as altered platelet responsiveness or endothelial dysfunction. This review focuses on the available data relating to use of individual N(t)RTI drugs and the drug class as a whole and CAD, with a focus on MI.
Key words:  Antiretroviral therapy      Human immunodeficiency virus      Coronary heart disease      Nucleotide reverse transcriptase inhibitors      Cardiovascular disease     
Published:  20 January 2014     

Cite this article: 

Patrick W.G. Mallon. Impact of Nucleoside Reverse Transcriptase Inhibitors on Coronary Heart Disease. Reviews in Cardiovascular Medicine, 2014, 15(S1): 21-29.

URL: 

https://rcm.imrpress.com/EN/10.3908.ricm15S1S005     OR     https://rcm.imrpress.com/EN/Y2014/V15/IS1/21

[1] Shanna J. Hardin, Mahavir Singh, Wintana Eyob, Jack C. Molnar, Rubens P. Homme, Akash K. George, Suresh C. Tyagi. Diet-induced chronic syndrome, metabolically transformed trimethylamine-N-oxide, and the cardiovascular functions[J]. Reviews in Cardiovascular Medicine, 2019, 20(3): 121-128.
[2] Wenyan Jiang, Mei Wang. New insights into the immunomodulatory role of exosomes in cardiovascular disease[J]. Reviews in Cardiovascular Medicine, 2019, 20(3): 153-160.
[3] Rudaynah A. Alali. A short review of proprotein convertase subtilisin/kexin type 9 inhibitors[J]. Reviews in Cardiovascular Medicine, 2019, 20(1): 1-8.
[4] Yun Tian, Pingji Deng, Bing Li, Jieqiong Wang, Ju Li, Yulan Huang, Yan Zheng. Treatment models of cardiac rehabilitation in patients with coronary heart disease and related factors affecting patient compliance[J]. Reviews in Cardiovascular Medicine, 2019, 20(1): 27-33.
[5] Jennifer G. Robinson, Karol E. Watson. Identifying Patients for Nonstatin Therapy[J]. Reviews in Cardiovascular Medicine, 2018, 19(S1): 1-8.
[6] Davide Bolignano, Anna Pisano, Graziella D’Arrigo. Pulmonary hypertension: a neglected risk condition in renal patients?[J]. Reviews in Cardiovascular Medicine, 2018, 19(4): 117-121.
[7] Peter A. McCullough, Aaron Y. Kluger, Kristen M. Tecson, Clay M. Barbin, Andy Y. Lee, Edgar V. Lerma, Zachary P. Rosol, Sivan L. Kluger, Janani Rangaswami. Inhibition of the Sodium–Proton Antiporter (Exchanger) is a Plausible Mechanism of Potential Benefit and Harm for Drugs Designed to Block Sodium Glucose Co-transporter 2[J]. Reviews in Cardiovascular Medicine, 2018, 19(2): 51-63.
[8] Alberto Palazzuoli, Helen Hashemi, Lauren C. Jameson, Peter A. McCullough. Hyperuricemia and Cardiovascular Disease[J]. Reviews in Cardiovascular Medicine, 2017, 18(4): 134-145.
[9] Claudio Ronco, Federico Ronco, Peter A. McCullough. A Call to Action to Develop Integrated Curricula in Cardiorenal Medicine[J]. Reviews in Cardiovascular Medicine, 2017, 18(3): 93-99.
[10] Boback Ziaeian, John Dinkler, Karol Watson. Implementation of the 2013 American College of Cardiology/American Heart Association Blood Cholesterol Guideline Including Data From the Improved Reduction of Outcomes: Vytorin Efficacy International Trial[J]. Reviews in Cardiovascular Medicine, 2015, 16(2): 125-130.
[11] Norman E. Lepor, Dean D. Fouchia, Peter A. McCulloughsup. New Vistas for the Treatment of Obesity: Turning the Tide Against the Leading Cause of Morbidity and Cardiovascular Mortality in the Developed World[J]. Reviews in Cardiovascular Medicine, 2014, 15(S2): 1-21.
[12] Virginia A. Triant. Epidemiology of Coronary Heart Disease in Patients With Human Immunodeficiency Virus[J]. Reviews in Cardiovascular Medicine, 2014, 15(S1): 1-8.
[13] Paolo Gresele, Emanuela Falcinelli, Stefania Momi, Daniela Francisci, Franco Baldelli. Highly Active Antiretroviral Therapy–related Mechanisms of Endothelial and Platelet Function Alterations[J]. Reviews in Cardiovascular Medicine, 2014, 15(S1): 9-20.
[14] Giovanni Guaraldi, Antonella Santoro, Chiara Stentarelli, Kety Luzi. Impact of Antiretroviral Medications on Fasting Lipid Parameters[J]. Reviews in Cardiovascular Medicine, 2014, 15(S1): 30-37.
[15] Peter Shalit. Management of Dyslipidemia in Patients With Human Immunodeficiency Virus[J]. Reviews in Cardiovascular Medicine, 2014, 15(S1): 38-46.
No Suggested Reading articles found!